May 2nd 2024
In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
Understanding RSV: What You Need to Know to Prevent and Treat Respiratory Syncytial Virus in Your Patients
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
3rd Annual International Congress on Pediatric Oncology
October 25, 2024
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More